Antibody-drug conjugate comprising antibody against human ROR1 and use for the same
US11707533B2 · kind B2 · utility
2Cited by
15References
38Claims
0Family size
Assignees
Inventors
- Yun Hee Park
- Ho-Young Song
- Hyun Min Ryu
- Sung Min Kim
- Ju Yuel Baek
- Ji Hye Oh
- Nara Han
- Hyoung Rae Kim
- Kyung Eun Park
- Hyeun Joung Lee
- Ju Young Lee
- Dae Hyuck Kang
- Young-Jae Yang
- Ji-Na You
- Yong Zu Kim
- Chang-Sun Lee
- Jeiwook Chae
- Jinwon Jung
- Juhee Kim
- Bora Lee
- Daehae Song
- Byungje Sung
- Donghoon Yeom
- Jaehyun EOM
- Youngeun Hong
- Jinhyung Ahn
- Yangsoon Lee
- Kyungjin Park
- Jiseon Yoo
- Minji Park
Key dates
| Filing date | Jul 27, 2020 |
| Grant date | Jul 25, 2023 |
| Priority date | — |
| Expiry date | Oct 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2803
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.